Pediatrix Q1 adjusted EPS $0.33; raises FY2025 EBITDA guidance to $220-240M

Pediatrix Medical Group, Inc.

2025-Q1 EPS reported $0.24 revenue$458,359,000

Net revenue $458M, down 7% YoY due to dispositions; same-unit revenue grew 6.2% on improved payor mix and volume.
Adjusted EBITDA $49.2M (up 32% YoY); GAAP EPS $0.24 vs $0.05; Adjusted EPS $0.33 vs $0.20.
Raised FY2025 Adjusted EBITDA guidance to $220-240M from $215-235M after strong Q1.
Cash from ops used $116.1M for seasonal incentive comp; total debt $611M, no revolver draw.
Same-unit volume: NICU days +2.0%, hospital-based +1.7%, office-based +2.6% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.